Researchers
Mijušković, Željko
Issue Date | Title | Author(s) | Type | М-cat. |
---|---|---|---|---|
2023 | Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial (✓) | Livingstone, E; Gogas c , H.; Kandolf-Sekulović, Lidija O.; ...; Mijušković, Željko P. ![]() ![]() | Article | 21M21 |